In BCC, participants who did not receive hedgehog pathway inhibitors or anti-PD-1/anti-PD-L1 will receive Vidutolimod weekly for 7 doses followed by every 3 weeks for up to 3 years. Here, CD274 is linked to skin basal cell carcinoma.